GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Greenwich Lifesciences GLSI · USD

Health Care · US listing · 🇺🇸 United States

Compare

16.52

+8.90%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

−$19.4m

FY2017FY2025

Free cash flow

−$9.9m

FY2017FY2025

Shareholders' equity

$353,217

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Gross profit−$1,779−$3,612−$3,612−$3,612−$3,612−$3,609−$3,607−$3,607−$3,607
Research and development$17.2m$15.5m$7.7m$6.5m$3.6m$1.1m$2.6m$1.3m$1.2m
Operating income−$19.4m−$17.6m−$9.3m−$8.0m−$4.6m−$1.9m−$3.4m−$1.7m−$1.6m
Net income−$19.4m−$17.4m−$8.9m−$7.8m−$4.6m−$1.9m−$3.4m−$1.7m−$1.6m
Diluted earnings per share-1.35-1.32-0.69-0.62-0.35-0.21-0.29-0.14-0.13

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$6.2m$4.1m$7.0m$13.5m$27.2m$28.7m$26,671$108,545$27,104
Cash and short-term investments$6.2m$4.1m$7.0m$13.5m$27.2m$28.7m$6,835$85,102$54
Total liabilities$5.8m$1.6m$294,406$262,905$385,172$1.0m$1.4m$10.2m$8.6m
Debt—————$280,000$640,000$9.9m$8.3m
Shareholders' equity$353,217$2.5m$6.7m$13.2m$26.8m$27.6m−$1.4m−$10.1m−$8.5m
Shares outstanding14m13m13m13m13m9m12m12m12m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−$9.9m−$7.3m−$6.5m−$6.2m−$4.3m−$1.2m−$293,267−$114,952−$120,847
Capital spending−$3−$3—−$3—————
Free cash flow−$9.9m−$7.3m−$6.5m−$6.2m−$4.3m−$1.2m−$293,267−$114,952−$120,847

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue—$3,558———$3,612——
Gross profit—$1,779——−$876−$903—−$903
Operating income−$4.0m−$5.7m−$7.9m−$4.2m−$4.0m−$2.8m−$8.1m−$2.7m
Net income−$3.9m−$5.7m−$7.9m−$4.2m−$4.0m−$2.7m−$8.0m−$2.7m
Diluted earnings per share-0.27-0.39-0.55-0.29-0.28-0.19-0.61-0.20
Cash from operations−$1.0m−$4.0m−$3.0m−$2.0m−$2.0m−$1.0m−$1.0m−$2.0m
Total assets$8.9m$10.5m$6.2m$3.8m$3.1m$2.8m$4.1m$5.8m
Cash and short-term investments$8.9m$10.5m—$3.8m$3.1m$2.7m—$5.8m
Shareholders' equity$3.1m$5.3m$353,217$2.2m$1.4m$1.3m$2.5m$5.0m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income34.2%59.8%—
Net income35.2%59.7%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings-15.5-8.5-15.2-24.6-68.7-172.1

Share price return

Finished calendar years

202520242023202220212020
Return1%20%-16%-57%-23%635%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.